Iodoform

Summary

Iodoform (CHEMBL1451116) is a phase-3 clinical-stage small molecule (ATC D09AA13).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: D09AA13
• Clinical trials: 4
• Chemistry: 393.732 Da · CHI3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1451116
Name	Iodoform
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6374
ChEBI	CHEBI:37758
ATC	D09AA13
Molecular formula	CHI3
Molecular weight	393.732
InChIKey	OKJPEAGHQZHRQV-UHFFFAOYSA-N

SMILES: C(I)(I)I

IUPAC name: iodoform

Also known as: Iodoform, Iodoformum, NSC-26251, SID17389850, SID26752992, SID144204675, SID144213091, SID144209587, IODOFORM

Patent coverage: 6,012 distinct patent families (14,152 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, 4’-phosphopantetheinyl transferase ffp, Polyunsaturated fatty acid lipoxygenase ALOX15, Aldehyde dehydrogenase 1A1, 3-hydroxyacyl-CoA dehydrogenase type-2, Lethal factor.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	3
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00947089	PHASE4	COMPLETED	Role of Oxidized Regenerated Cellulose (ORC) Applied to Dirty Surgical Wounds
NCT03084601	PHASE4	COMPLETED	Evaluation of Postoperative Pain After Using 3MIX-TATIN Versus Calcium Hydroxide Iodoform Paste In Necrotic Primary Molars Treated by Lesion Sterilization and Tissue Repair Therapy
NCT03741894	PHASE4	UNKNOWN	Examination of the Prevention and Treatment Modalities of Alveolitis in Relation With Impacted Teeth Surgery
NCT06755502	Not specified	NOT_YET_RECRUITING	Garlic Oil As Root Filling Material in Primary Molars

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).